Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
暂无分享,去创建一个
Robin L. Jones | J. Blay | O. Mir | H. Joensuu | A. Italiano | A. D. Dei Tos | P. Rutkowski | A. Le Cesne | P. Hohenberger | P. Casali | H. Gelderblom | A. Gronchi | J. Martín-Broto | P. Reichardt | B. Vincenzi | M. Silletta | G. Tonini | W. V. van Houdt | M. Pantaleo | M. Nannini | N. Steeghs | S. Bauer | S. Gasperoni | G. Grignani | A. Napolitano | A. Brunello | N. IJzerman | M. Fiocco | M. Sbaraglia | N. Hindi | I. Desar | G. Badalamenti | S. Gennatas | E. Fumagalli | M. Spalato Ceruso | T. de Pas | J. Falkenhorst | T. D. De Pas
[1] J. Blay,et al. Starting Imatinib at 400 mg Daily in Patients with Gastrointestinal Stromal Tumors Harboring KIT Exon 9 Mutations: A Retrospective, Multicenter Study , 2021, Targeted Oncology.
[2] E. Wardelmann,et al. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up. , 2020, JAMA oncology.
[3] B. Vincenzi,et al. New frontiers in the medical management of gastrointestinal stromal tumours , 2019, Therapeutic advances in medical oncology.
[4] C. Dobler,et al. Clinicians’ cognitive biases: a potential barrier to implementation of evidence-based clinical practice , 2018, BMJ Evidence-Based Medicine.
[5] Kamlesh Khunti,et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician , 2018, Advances in Therapy.
[6] Robin L. Jones,et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] E. Wardelmann,et al. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] P. Casali,et al. Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis , 2015, Oncotarget.
[9] C. Antonescu,et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[11] E. Wardelmann,et al. Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations: Update on Genotype-Phenotype Correlation and Validation of a High-Resolution Melting Assay for Mutational Testing , 2013, The American journal of surgical pathology.
[12] Aki Vehtari,et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. , 2012, JAMA.
[13] Aki Vehtari,et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. , 2012, The Lancet. Oncology.
[14] Gary King,et al. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference , 2011 .
[15] J. Blay,et al. The role of high‐dose imatinib in the management of patients with gastrointestinal stromal tumor , 2010, Cancer.
[16] F. Duffaud. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] C. Antonescu,et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial , 2009, The Lancet.
[18] Joseph Schlessinger,et al. Structural Basis for Activation of the Receptor Tyrosine Kinase KIT by Stem Cell Factor , 2007, Cell.
[19] J. Fletcher,et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Lasota,et al. Gastrointestinal stromal tumors: pathology and prognosis at different sites. , 2006, Seminars in diagnostic pathology.
[21] L. Rönnstrand,et al. Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism , 2006, British Journal of Cancer.
[22] E. Musulen,et al. Gastrointestinal stromal tumors , 2006, Abdominal Imaging.
[23] K. Wilson,et al. Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase* , 2004, Journal of Biological Chemistry.
[24] N. Socci,et al. Gene Expression in Gastrointestinal Stromal Tumors Is Distinguished by KIT Genotype and Anatomic Site , 2004, Clinical Cancer Research.
[25] A. D. Van den Abbeele,et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] D. Tuveson,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.
[27] Duc Hung Le,et al. SHP-1 Binds and Negatively Modulates the c-Kit Receptor by Interaction with Tyrosine 569 in the c-Kit Juxtamembrane Domain , 1998, Molecular and Cellular Biology.
[28] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.
[29] P. Grambsch,et al. Proportional hazards tests and diagnostics based on weighted residuals , 1994 .
[30] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .